Squarepoint
AZN icon

Squarepoint’s AstraZeneca AZN Stock Holding History

Squarepoint’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,450
Closed -$24M – 4265
2025
Q4 		$24M Buy
130,450
+54,900
+73% +$9.63M 0.03% 661
2025
Q3 		$11.6M Sell
75,550
-30,000
-28% -$4.54M 0.01% 1002
2025
Q2 		$14.8M Buy
105,550
+11,350
+12% +$1.59M 0.02% 903
2025
Q1 		$13.8M Sell
94,200
-107,750
-53% -$15.6M 0.02% 873
2024
Q4 		$26.5M Buy
201,950
+4,750
+2% +$665K 0.03% 629
2024
Q3 		$30.7M Buy
197,200
+108,300
+122% +$17.5M 0.05% 412
2024
Q2 		$13.9M Sell
88,900
-85,850
-49% -$12.9M 0.02% 767
2024
Q1 		$23.7M Buy
174,750
+58,950
+51% +$7.81M 0.04% 537
2023
Q4 		$15.6M Buy
115,800
+30,200
+35% +$3.93M 0.03% 690
2023
Q3 		$11.6M Buy
85,600
+27,900
+48% +$3.81M 0.03% 733
2023
Q2 		$8.26M Sell
57,700
-198,900
-78% -$29.3M 0.03% 776
2023
Q1 		$35.6M Buy
256,600
+92,850
+57% +$12.5M 0.15% 136
2022
Q4 		$22.2M Buy
163,750
+136,400
+499% +$17.1M 0.09% 229
2022
Q3 		$3M Buy
27,350
+19,650
+255% +$2.49M 0.02% 1047
2022
Q2 		$1.02M Buy
+7,700
New +$1.01M 0.01% 1588

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Squarepoint's AZN Position: Q1 2026 in Review

Squarepoint opened a new position in AstraZeneca (AZN) in Q1 2026: 9,582 shares worth $1.89M. The stake represents ﹤0.01% of the portfolio and ranks #2224 among its holdings. This is a return to the name: Squarepoint previously reported a position in AZN as recently as Q3 2025.

Squarepoint first reported a position in AZN in Q4 2016 and has held it in 27 quarters since. The position peaked at $34.7M in Q4 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Squarepoint held 9,582 shares of AstraZeneca worth $1.89M as of Q1 2026.
  • AstraZeneca was a new Squarepoint position in Q1 2026.
  • AstraZeneca made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2224 holding.
  • Squarepoint first reported a position in AstraZeneca in Q4 2016 and has held it in 27 quarters since.
  • Squarepoint's AstraZeneca position peaked at $34.7M in Q4 2023.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.